Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA, Ozdemir N, Özatlı T, Yazıcı O, Aksoy S, Ekinci AS, Yazılıtaş D, Günaydın Y, Oksuzoglu B, Benekli M, Zengin N. Sendur MA, et al. Among authors: yazilitas d. Med Oncol. 2014 Sep;31(9):153. doi: 10.1007/s12032-014-0153-y. Epub 2014 Aug 7. Med Oncol. 2014. PMID: 25099765
Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY, Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Tonyali O, et al. Among authors: yazilitas d. J Cancer Res Clin Oncol. 2012 Dec;138(12):2145-51. doi: 10.1007/s00432-012-1296-x. Epub 2012 Aug 10. J Cancer Res Clin Oncol. 2012. PMID: 22878681
Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab.
Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O, Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Tonyali O, et al. Among authors: yazilitas d. Onkologie. 2013;36(10):554-8. doi: 10.1159/000355156. Epub 2013 Sep 16. Onkologie. 2013. PMID: 24107908
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.
Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Kefeli U, et al. Among authors: yazilitas d. Oncol Lett. 2013 Aug;6(2):605-611. doi: 10.3892/ol.2013.1408. Epub 2013 Jun 17. Oncol Lett. 2013. PMID: 24137379 Free PMC article.
Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.
Uyeturk U, Oksuzoglu B, Akman T, Turker I, Sener N, Tastekin D, Bal O, Berk V, Arslan UY, Urakci Z, Bilir C, Yilmaz U, Yazilitas D, Ulas A, Sonmez OU, Budakoglu B, Cihan S, Uysal M. Uyeturk U, et al. Among authors: yazilitas d. Med Oncol. 2014 Apr;31(4):929. doi: 10.1007/s12032-014-0929-0. Epub 2014 Mar 22. Med Oncol. 2014. PMID: 24659267
Recurrence risk and prognostic parameters in stage I rectal cancers.
Cihan S, Kucukoner M, Ozdemir N, Dane F, Sendur MA, Yazilitas D, Urakci Z, Durnali A, Yuksel S, Aksoy S, Colak D, Seker MM, Taskoylu BY, Oguz A, Isikdogan A, Zengin N. Cihan S, et al. Among authors: yazilitas d. Asian Pac J Cancer Prev. 2014;15(13):5337-41. doi: 10.7314/apjcp.2014.15.13.5337. Asian Pac J Cancer Prev. 2014. PMID: 25040998 Free article.
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Duran AO, Karaca H, Besiroglu M, Bayoglu IV, Menekse S, Yapici HS, Yazilitas D, Bahceci A, Uysal M, Sevinc A, Hacibekiroglu I, Aksoy A, Tanriverdi O, Arpaci E, Inanc M, Dane F, Ozkan M. Duran AO, et al. Among authors: yazilitas d. Asian Pac J Cancer Prev. 2014;15(23):10375-9. doi: 10.7314/apjcp.2014.15.23.10375. Asian Pac J Cancer Prev. 2014. PMID: 25556478 Free article.
Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
Yazilitas D, Sendur MA, Karaca H, Ozdemir N, Aksoy S, Berk V, Yazici O, Ozturk B, Ozkan M, Zengin N, Altundag K. Yazilitas D, et al. Asian Pac J Cancer Prev. 2015;16(4):1471-7. doi: 10.7314/apjcp.2015.16.4.1471. Asian Pac J Cancer Prev. 2015. PMID: 25743817 Free article.
35 results